Sinopharm Group Co (FRA:X2S) EBIT : €2,167 Mil (TTM As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co EBIT?

Sinopharm Group Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €1,147 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €2,167 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sinopharm Group Co's annualized ROC % for the quarter that ended in Jun. 2024 was 7.58%. Sinopharm Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 17.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sinopharm Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 13.77%.

Sinopharm Group Co EBIT Historical Data

The historical data trend for Sinopharm Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co EBIT Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

2,391.20

2,884.56

2,990.29

2,885.61

2,195.10

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial															1,662.30	1,356.80	1,533.62	1,146.98	1,020.23

Competitive Comparison of Sinopharm Group Co's EBIT

For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's EV-to-EBIT falls into.

Sinopharm Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2,167 Mil.

Sinopharm Group Co (FRA:X2S) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sinopharm Group Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	2486.138 * ( 1 - 22.34% )	/	( (21951.179	+	28966.422)	/ 2 )
=	1930.7347708	/	25458.8005
=	7.58 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	49238.547	-	19092.509	-	( 8194.859	-	max(0, 31014.105	-	43258.982	+	8194.859	))
=	21951.179

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	55010.23	-	20494.892	-	( 5548.916	-	max(0, 36270.003	-	48963.439	+	5548.916	))
=	28966.422

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sinopharm Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2293.954	/	( ( (2555.412 + max(7073.962, 0))	+	(2573.713 + max(14247.283, 0)) )	/	2 )
=	2293.954	/	( ( 9629.374	+	16820.996 )	/	2 )
=	2293.954	/	13225.185
=	17.35 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(21704.665	+	7709.217	+	1414.551)	-	(19092.509	+	0	+	4661.962)
=	7073.962

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(30004.11	+	8815.007	+	1268.152)	-	(20494.892	+	0	+	5345.094)
=	14247.283

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sinopharm Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	2167.21	/	15737.169
	=	13.77 %

Sinopharm Group Co EBIT Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (FRA:X2S) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA 01099:Hong Kong

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

No Headlines